Anti-chlamydophila antibiotic combination therapy in the treatment of patients with Coronary Heart Disease

INTERVENTION: Anti‐Chlamydaphila antibiotic combination: Doxycycline, Azithromycin & Rifabutin Dose: 50mg Doxycycline, 250mg Azithromycin & 150mg Rifabutin (3 separate capsules) daily (days 1 to 7), 50mg Doxycycline, 250mg Azithromycin & 150mg Rifabutin (3 separate capsules) twice daily (days 8 to 90). Duration: 90 days Mode: oral capsules CONDITION: Chlamydophila pneumoniae infection Coronary Heart Disease PRIMARY OUTCOME: To evaluate the effect of antibiotic combination therapy on objective measures of improvement in coronary flow as determined by fractional flow reserve (FFR) in subjects undergoing percutaneous coronary intervention (PCI) with non‐critical lesions in non‐culprit arteries. SECONDARY OUTCOME: To evaluate angiographic stenoses changes (QCA) via diagnostic angiography during the ACAC trial. To record major adverse clinical events (MACE), including death, recurrent myocardial infarction, stroke and major bleeding via investigator adverse event reporting INCLUSION CRITERIA: 1. Males and females (without childbearing potential as evidenced by hysterectomy, tubal ligation or at least one year post‐menopause) aged 18 to 80 years, inclusive. 2. Ability to provide written informed consent to participate in the study. 3. Subjects with documented recent acute coronary syndrome (ACS) or evidence of myocardial ischemia. 4. Subjects who have a culprit lesion suitable for PCI, and a non‐critical lesion in another vessel suitable for staged PCI with an FFR of <0.80, for subjects undergoing diagnostic angiography and FFR without ad hoc PCI. 5. No serious co‐morbidities, which might interfere with the subject’s ability to enter the study. 6. Able to communicate effectively with the study team and to comply with the protocol.